Dr Andrew Kuykendall speaks to ecancer about a phase 2 study that evaluates fedratinib, a JAK2 inhibitor with a broader kinase inhibition profile, in patients with MDS/MPN overlap syndromes and chronic neutrophilic leukaemia, diseases with limited treatment options and poor prognosis.

Fedratinib demonstrated encouraging clinical activity, with 44% of patients achieving a response at 24 weeks, including meaningful reductions in spleen volume and symptom burden.

Dr Kuykendall highlights that improvements were particularly notable in patients with proliferative disease features, and responses were observed across multiple MDS/MPN subtypes.

Survival outcomes were promising, with median progression-free and overall survival reaching nearly 37 months.

The safety profile was consistent with prior experience, with manageable adverse events.

These findings suggest fedratinib may offer an effective treatment option for patients with molecularly complex MDS/MPN disorders, supporting further investigation in this setting.